NICE still wants more info on RoActemra for RA patients
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, has again asked Roche for more information on RoActemra (tocilizumab) before it decides whether to recommend it for treating some rheumatoid arthritis (RA) patients on the NHS.
You may also be interested in...
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.
Plans for EU-wide Joint Clinical assessments will come under scrutiny at an EU council meeting next week.
Pfizer’s Ibrance has won conditional reimbursement in England while more data is gathered to reduce some uncertainty.